干扰素α联合化疗药对乳腺癌细胞株协同抗增殖作用及 机制研究-外科学专业论文.docxVIP

万方数据 万方数据 目 录 中文摘要···········································································································1 英文摘要···········································································································5 英文缩写·········································································································10 研究论文 干扰素 α 联合化疗药对乳腺癌细胞株协同抗增殖作用及机制 研究 前言·········································································································11 材料和方法·····························································································12 结果·········································································································22 附图·········································································································25 附表·········································································································32 讨论·········································································································33 结论·········································································································35 参考文献·································································································36 综述 干扰素 α 的研究进展 38 致谢·················································································································51 个人简历·········································································································52 中 中 文 摘 要 PAGE 10万方数据 PAGE 10 万方数据 干扰素 α 联合化疗药对乳腺癌细胞株 协同抗增殖作用及机制研究 摘 要 目的：乳腺癌在世界范围内发病率呈逐年上升趋势，现已居在我国女 性恶性肿瘤之首，是威胁女性健康的重要因素。从 20 世纪 70 年代美国肿 瘤学家 Fisher 提出乳腺癌是一种全身性疾病，乳腺癌的全身综合性治疗开 始得到重视，形成了一种以局部治疗为主，同时联合放化疗及内分泌治疗 为辅的综合治疗模式。近年来，随着人们对肿瘤生物学特性研究的不断深 入，生物治疗逐渐被提升至重要地位，主要包括靶向治疗、基因治疗、免 疫细胞治疗等。干扰素 α（interferon alpha，IFN-α）作为应用较早的免疫 调节因子，同时也较早的应用于肿瘤临床治疗，现已用于治疗 14 种以上 类型的肿瘤，且具有良好的效果及较小的毒副反应，但尚未应用于乳腺癌。 本文通过研究干扰素 α 联合化疗药作用于乳腺癌细胞株，探究两者之间 是否具有协同抗增殖作